X-082 manufacturers
- Vorolanib
-
- $108.00
-
2026-07-27
- CAS:1013920-15-4
- Purity: 98.73%
- Supply Ability: 10g
|
| Product Name: | X-082 | | Synonyms: | X-082;CM 082;CM-082;X 82;X82;X-82;1H-Pyrrole-3-carboxamide, N-[(3S)-1-[(dimethylamino)carbonyl]-3-pyrrolidinyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-;VEGFR,PDGFR,X82,Vascular endothelial growth factor receptor,CM 082,transporter,angiogenesis,CM-082,X 82,Vorolanib,ATP-binding,tyrosine,ABC,Inhibitor,ABCG2,inhibit,Platelet-derived growth factor receptor,TKI,cassette,orally,kinase,HUVECs | | CAS: | 1013920-15-4 | | MF: | C23H26FN5O3 | | MW: | 439.48 | | EINECS: | | | Product Categories: | | | Mol File: | 1013920-15-4.mol |  |
| | X-082 Chemical Properties |
| Boiling point | 657.8±55.0 °C(Predicted) | | density | 1.37±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO: 27 mg/mL (61.44 mM) | | form | Solid | | pka | 11.70±0.20(Predicted) | | color | Light yellow to yellow |
| | X-082 Usage And Synthesis |
| Uses | Vorolanib is an oral anti-VEGFR/PDGFR/CSF1R tyrosine kinase inhibitor that can inhibit angiogenesis in vitro and in vivo. | | in vivo | Vorolanib (CM082; 20 mg/kg; gavage; once every 2 days; 1 h before SKF 104864A; for 23 days) enhances the anti-tumor effect of SKF 104864A on xenografts of ABCG2-overexpressing cells[1].
Vorolanib (80 mg/kg; twice daily; for 21 days) has antitumor activity combined with ZD1839 (10 mg/kg; q.d; for 21 days) on H3255 tumor xenograft (female BALB/c nude mice aged five weeks)[2].
|
| | X-082 Preparation Products And Raw materials |
|